|
?:abstract
|
-
Severe COVID-19 is defined as patients with an oxygen saturation (SpO2) 94% on room air or requiring supplemental oxygen or requiring mechanical ventilation or requiring extracorporeal membrane oxygenation (ECMO), a heart-lung bypass machine, in an in-hospital setting intravenously, and in doses described in the authorized Fact Sheet 3,6 Although most infections are self-limited, about 15% of infected adults develop severe pneumonia that requires treatment with supplemental oxygen and an additional 5% progress to critical illness with hypoxaemic respiratory failure, acute respiratory distress syndrome, and multiorgan failure that necessitates ventilatory support, often for several weeks 7 At least half of patients with coronavirus disease 2019 (COVID-19) requiring invasive mechanical ventilation have died in hospital and the associated burden on health-care systems, especially intensive care units, has been overwhelming in several affected countries 8,9,10 Pregnancy is a state of partial immune suppression that makes pregnant women more vulnerable to viral infections, and the morbidity is higher even with seasonal influenza [ ]the COVID- 19 pandemic may have serious consequences for pregnant women 11 Several preexisting and potential drug candidates, including remdesivir, has been considered Because of the urgency of the COVID-19 outbreak and the uncertainties about its management during pregnancy, we aimed to provide a literature review on the putative effectiveness and safety of remdesivir which exhibits promising in vitro antiviral activity and preliminary clinical experiences for COVID-19 in pregnant women Remdesivir appears to have a favorable clinical safety profile, as reported based on experience in approximately 500 persons, including healthy volunteers and patients treated for acute Ebola virus infection, and supported by our data (on file and shared with the World Health Organization [WHO])19
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}